You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Gantenerumab

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Gantenerumab?

Gantenerumab is an investigational drug.

There have been 14 clinical trials for Gantenerumab. The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2020.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche, National Institute on Aging (NIA), and Eli Lilly and Company.

There are six US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for Gantenerumab
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)Hoffmann-La RochePhase 3
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)Hoffmann-La RochePhase 3
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Hoffmann-La RochePhase 3

See all Gantenerumab clinical trials

Clinical Trial Summary for Gantenerumab

Top disease conditions for Gantenerumab
Top clinical trial sponsors for Gantenerumab

See all Gantenerumab clinical trials

US Patents for Gantenerumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gantenerumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Gantenerumab   Start Trial Intranasal administration of guanidinylated aminoglycosides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
Gantenerumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Gantenerumab   Start Trial Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gantenerumab

Drugname Country Document Number Estimated Expiration Related US Patent
Gantenerumab Australia 2013220749 2032-02-15   Start Trial
Gantenerumab Brazil 112014019627 2032-02-15   Start Trial
Gantenerumab Canada 2862476 2032-02-15   Start Trial
Gantenerumab China 104114705 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.